Concurrences is pleased to invite you its next Law & Economics Webinar dedicated to the Aspen decision.
On 10 February 2021, the European Commission accepted commitments from Aspen pursuant to Article 9(1) of Regulation 1/2003 to reduce its prices by 73% on average in Europe for six off-patent cancer medicines.
In this webinar supported by Covington & Burling LLP and Charles River Associates, the speakers will discuss the legal and economic highlights of the decision with members of the case-team and the CET.
Harald MISCHE | Case Handler - Antitrust : Pharma and Health services, DG COMP, Brussels [bio]
Tom VIEBIG | Case Handler - Antitrust : Pharma and Health services, DG COMP, Brussels [bio]
Lluís SAURI ROMERO | Economic Analyst - Economist (CET), DG COMP, Brussels [bio]
Raphaël DE CONINCK | Vice President, CRA, Brussels [bio]
Horst HENSCHEN | Of Counsel, Covington & Burling, Brussels/Frankfurt [bio]
Chair : Miranda COLE | Partner, Covington & Burling, Brussels/London [bio]
If you would like to read about this event’s topic, you can access the following Concurrences documents. If you do not have access, please inquire for Subscription here.
1. European Commission, The EU Commission accepts commitments made by a pharmaceutical company to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns (Aspen), 10 February 2021, e-Competitions February 2021, Art. N° 99249
2. Kyriakos Fountoukakos, Max Kaufman, Kristien Geeurickx, Agathe Célarié, The EU Commission accepts the commitment offered by a pharmaceutical company to reduce drug prices by 73% (Aspen), 10 February 2021, e-Competitions February 2021, Art. N° 99565
Conference accredited by the Paris Bar.
This event is organised by Concurrences Review and is co-sponsored by legal and/or economic partners. The attendee list will be communicated to the speakers. By registering for this webinar, you are submitting your information to the webinar organisers who will use it to communicate with you regarding this event and their other services. This webinar will be recorded. If your question is selected for the Q&A session, you are consenting to be recorded.
The official hashtag of this event on our social media is #AspenDecision. Use it to get updated and add your inputs to the discussions.
You can check news on this event on our Twitter, Linkedin Company page, Linkedin Group or Instagram.